nomacopan

{
  "id": "MLC-T-ONC-015536",
  "term": "nomacopan",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant small peptide inhibitor of the terminal complement pathway protein C5 originally derived from a protein in the saliva of the Ornithodoros moubata tick, with potential anti-inflammatory and cytoprotective activities. Upon administration, nomacopan targets and binds to a unique site on the terminal complement protein C5, which blocks C5 cleavage into the pro-inflammatory components C5a and C5b, and prevents the C5b-dependent assembly of the membrane-attack complex (MAC; C5b-9). This prevents MAC-mediated lysis and destruction of red blood cells (RBCs) in paroxysmal nocturnal hemoglobinuria (PNH) and prevents tissue destruction in various other complement-mediated inflammatory and autoimmune diseases. In addition, this C5 inhibitor targets, binds to and inhibits the activity of leukotriene B4 (LTB4), thereby further preventing inflammatory-mediated cell destruction.",
  "synonyms": [
    "recombinant Ornithodoros moubata saliva-derived small protein complement C5 inhibitor",
    "rEV576",
    "recombinant EV576",
    "complement C5-inhibitor rEV576",
    "recombinant OmCI",
    "recombinant Ornithodoros moubata complement inhibitor"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nomacopan/"
}